Preparing for bioterrorism: category A agents.
September 11, 2001, brought the possibility of biologic acts of terrorism against the United States into the national consciousness. As the American people brace themselves for this new threat to the national well-being, clinicians must understand how to prevent, recognize, and treat the biologic agents that could be used in terrorist attacks. This article discusses the most likely biologic agents, including diagnostic laboratory procedures, treatment options, psychological effects, special populations, and reporting requirements.
Persell
D J
DJ
Arkansas State University, USA.
Arangie
P
P
Young
C
C
Stokes
E N
EN
Payne
W C
WC
Skorga
P
P
Gilbert-Palmer
D
D
D000881:Anthrax / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D023482:Bioterrorism; D001906:Botulism / Q000188:drug therapy / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000627:therapeutic use; D006801:Humans; D010930:Plague / Q000188:drug therapy / Q000517:prevention & control*; D011314:Preventive Health Services / Q000458:organization & administration*; D012899:Smallpox / Q000276:immunology / Q000517:prevention & control; D012900:Smallpox Vaccine / Q000276:immunology / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014406:Tularemia / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D012900:Smallpox Vaccine; D002939:Ciprofloxacin; D013307:Streptomycin